Article Information
History
- April 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jacob E. Simmering, PhD1,2,*,
- Michael J. Welsh, MD1,2,3,4,5,
- Jordan Schultz, PharmD4,6,7 and
- Nandakumar S. Narayanan, MD, PhD2,6
- 1Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
- 2Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
- 3Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
- 4Department of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
- 5Howard Hughes Medical Institute, University of Iowa, Iowa City, Iowa, USA
- 6Department of Psychiatry, Roy J. and Lucille A. Carver College of Medicine Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
- 7Division of Pharmacy Practice and Sciences, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA
- ↵*Address correspondence to: Jacob E Simmering, 169 Newton Road, 5332 PBDB, Iowa City, Iowa, 52242, Phone: (319)-335-3053, jacob-simmering{at}uiowa.edu
Posted April 01, 2022.
Use of glycolysis enhancing drugs has less risk of Parkinson’s disease than 5α-reductase inhibitors
